IMUX raises €10.0M Series A round

Completion of Series A round to accelerate Phase 2 development of IMU-838 in inflammatory bowel diseases.

Source: https://www.imux.com/immunic-therapeutics-adds-new-investors-and-completes-series-a-financing-round-of-total-eur-31-7-million/